Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

Also called NCT05767346

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
  • Cytokinetics Registry lists this organization as the lead sponsor
  • Sanofi Registry lists this organization as a collaborator
Registry
  • NCT NCT05767346
Other papers using this trial's data
  • Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial Journal of the American College of Cardiology, 2026-03-03 DOI, PubMed 41348072
  • Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy The New England journal of medicine, 2025-09-11 DOI, PubMed 40888697
  • Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Journal of the American College of Cardiology, 2025-12-16 DOI, PubMed 40932433
  • Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy Journal of the American College of Cardiology, 2026-03-03 DOI, PubMed 41493295
  • Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial JAMA cardiology, 2026-08-01 DOI, PubMed 42307914, PMC13276672 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05767346. Randomized; triple masking; primary purpose treatment. Start 2023-06-20 (actual); primary completion 2025-02-28 (actual). Results posted on 2026-06-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Acronym
MAPLE-HCM
Condition
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention (Drug)
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Intervention (Drug)
Placebo to match aficamten
Intervention (Drug)
Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
Intervention (Drug)
Placebo to match metoprolol succinate
Lead sponsor
Cytokinetics (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct05767346
Content hash
8ae7b46dc80b651c628ee44da6ed1e01256ee5805f17edb13c746d521308256f